ResMed Inc stock (AU000000RMD6): Sleep apnea and respiratory care leader posts strong growth outlook

ResMed Inc reports solid first?quarter 2025 results and upbeat growth guidance, highlighting its recurring revenue model in sleep apnea and respiratory care.

ResMed Inc, a global leader in sleep apnea and respiratory care devices, has reported strong first?quarter 2025 results and reiterated a positive growth outlook, reinforcing its position in the out?of?hospital medical device market. The company’s combination of hardware, consumables, and cloud?connected software continues to drive recurring revenue and margin expansion, according to its latest earnings release and investor commentary.

As of: 10.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc
• Sector/industry: Healthcare / Medical devices
• Headquarters/country: United States
• Core markets: United States, Europe, Asia?Pacific
• Key revenue drivers: CPAP machines, masks and accessories, cloud?connected respiratory software
• Home exchange/listing venue: New York Stock Exchange (NYSE: RMD)
• Trading currency: USD

ResMed Inc: core business model

ResMed Inc designs, manufactures, and markets medical devices and cloud?based software applications to diagnose, treat, and manage respiratory disorders, with a primary focus on sleep?disordered breathing such as obstructive sleep apnea and chronic obstructive pulmonary disease. The company’s products are used in home, long?term care, and hospital settings, emphasizing out?of?hospital care and remote patient monitoring.

The business model resembles a “razor?and?blade” structure: initial sales of CPAP machines and ventilators generate follow?on, recurring revenue from masks, tubing, filters, and other consumables that patients replace regularly. This recurring stream is further supported by subscription?style software and connectivity services that enable clinicians to monitor therapy adherence and device performance remotely.

ResMed’s global footprint spans the United States, Europe, and Asia?Pacific, where it serves healthcare providers, payers, and patients. The company’s emphasis on connected health platforms positions it at the intersection of medical devices and digital health, a segment that has attracted growing interest from US investors seeking exposure to long?term healthcare trends.

Main revenue and product drivers for ResMed Inc

ResMed’s revenue is split between device sales and recurring supply items, with the latter forming a significant and growing share of total sales. Over the trailing twelve months, the company’s recurring supply segment generated roughly 1.96 billion dollars and accounted for about 36% of total revenue, according to third?party financial analysis published in early 2026.

Key product lines include continuous positive airway pressure (CPAP) and bilevel therapy devices, masks and headgear, and ventilators for chronic respiratory conditions. In parallel, ResMed’s cloud?connected platforms, such as its AirView and AirSense ecosystems, provide data analytics and remote monitoring tools that help clinicians optimize treatment plans and improve patient adherence.

Why ResMed Inc matters for US investors

For US investors, ResMed offers leveraged exposure to several structural healthcare trends: rising prevalence of sleep apnea and chronic respiratory diseases, aging populations, and the shift toward home?based and remote care. The company’s listing on the New York Stock Exchange and its substantial US revenue base make it a relevant name within the broader healthcare and medical?device sectors.

Analysts have highlighted ResMed’s strong execution and recurring?revenue profile, even as some note that the stock trades at a premium valuation relative to peers. A recent commentary from Zacks Investment Research dated May 5, 2026, described ResMed as a “strong growth stock” with a Zacks Rank of #3 (Hold) and a Value?Growth?Momentum (VGM) Score of A, underscoring its solid fundamentals despite a relatively rich multiple.

Conclusion

ResMed Inc continues to benefit from a durable demand backdrop for sleep apnea and respiratory care devices, supported by a recurring?revenue model and an expanding digital health platform. Recent earnings and commentary point to solid growth and margin performance, even as the stock’s valuation remains elevated.

US investors considering ResMed should weigh the company’s strong market position and recurring revenue streams against potential risks such as regulatory changes, reimbursement pressures, and competitive dynamics in the medical?device and digital?health space. As with any equity investment, diversification and a clear understanding of risk tolerance are important when evaluating exposure to ResMed Inc.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.